← Leaderboards
Aleksander Skardal
Ohio State University
$823,858
Attributed
$1,776,924
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $536.3K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,776,924 · 4
By mechanism
R21$1,776,924 · 4
Top collaborators
- Joal D Beane2 shared
- Priya Harakh Dedhia2 shared
- Jennifer Leight2 shared
- Roy Ervin Strowd2 shared
- Allan Tsung2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Swagata Goswami$644,678
- Priya Harakh Dedhia$207,957
- Jennifer Leight$129,207
- Michael A Caligiuri$65,062,344
- Joal D Beane$198,219
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMicrofluidicsTechnologyOrganoidsIn VitroCellsHeterogeneityTherapeutic InterventionTissuesPhenotypeNeoplastic CellExtracellular MatrixDevicesTumor MicroenvironmentKineticsEffective TherapyMalignant NeoplasmsCell ProliferationMicrofluidic MicrochipsResponse3-DimensionalHydrogelsImmuneBiological
Grant awards (8)
A matrix metalloproteinase biosensor-functionalized metastasis-on-a-chip platform for evaluating adrenocortical carcinoma progression$206,689
R21 · FY2024 · CA · contact PI
A matrix metalloproteinase biosensor-functionalized metastasis-on-a-chip platform for evaluating adrenocortical carcinoma progression$180,933
R21 · FY2023 · CA · contact PI
Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)$177,924
R21 · FY2023 · CA · contact PI
Organoid modeling of pre-metastatic niche formation in the liver by primary colorectal tumor secreted factors$177,461
R21 · FY2023 · CA · contact PI
Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)$218,513
R21 · FY2022 · CA · contact PI
Organoid modeling of pre-metastatic niche formation in the liver by primary colorectal tumor secreted factors$218,068
R21 · FY2022 · CA · contact PI
Predicting Tumor Heterogeneity Evolution After Therapy in Patient-derived Ex Vivo Glioblastoma Organoids$294,336
R21 · FY2019 · CA · contact PI
Predicting Tumor Heterogeneity Evolution After Therapy In Patient-Derived Ex Vivo Glioblastoma Organoids$303,000
R21 · FY2018 · CA · contact PI